| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Radek C Skoda | |
| Adrian Duek | |||
| Jean Grisouard | |||
| P2860 | cites work | Conditional deletion of Jak2 reveals an essential role in hematopoiesis throughout mouse ontogeny: implications for Jak2 inhibition in humans | Q21133609 |
| The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes | Q22299206 | ||
| A novel activating, germline JAK2 mutation, JAK2R564Q, causes familial essential thrombocytosis. | Q43642917 | ||
| Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia | Q43960584 | ||
| MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients | Q44008600 | ||
| Mutations and prognosis in primary myelofibrosis | Q44429606 | ||
| Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin | Q44756897 | ||
| A novel role for STAT1 in regulating murine erythropoiesis: deletion of STAT1 results in overall reduction of erythroid progenitors and alters their distribution | Q44948873 | ||
| Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms | Q45770967 | ||
| From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms | Q45778614 | ||
| Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clones | Q46146410 | ||
| Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F. | Q46220254 | ||
| Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome | Q46355702 | ||
| The genetic basis of myeloproliferative disorders | Q46892252 | ||
| Letter: Bone-marrow responses in polycythemia vera | Q47871256 | ||
| Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms | Q47960630 | ||
| Loss of Stat1 decreases megakaryopoiesis and favors erythropoiesis in a JAK2-V617F-driven mouse model of MPNs. | Q50471594 | ||
| A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. | Q51768323 | ||
| Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. | Q51806902 | ||
| Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. | Q53307880 | ||
| Letter: Tinel sign in carpal-tunnel syndrome. | Q54027944 | ||
| Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. | Q54225327 | ||
| Deletion of Stat3 in hematopoietic cells enhances thrombocytosis and shortens survival in a JAK2-V617F mouse model of MPN. | Q54296338 | ||
| Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms. | Q54336529 | ||
| Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia. | Q54511975 | ||
| Germline JAK2 mutation in a family with hereditary thrombocytosis. | Q54524902 | ||
| EZH2 mutational status predicts poor survival in myelofibrosis. | Q54560112 | ||
| Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors | Q57219643 | ||
| The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients | Q58455624 | ||
| Pathologic consequences of STAT3 hyperactivation by IL-6 and IL-11 during hematopoiesis and lymphopoiesis | Q62818283 | ||
| The threshold of gp130-dependent STAT3 signaling is critical for normal regulation of hematopoiesis | Q62818327 | ||
| Sequential gain of mutations in severe congenital neutropenia progressing to acute myeloid leukemia | Q62927037 | ||
| Polycythemia vera: stem-cell and probable clonal origin of the disease | Q34067020 | ||
| Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. | Q34074931 | ||
| Distinct regions of c-Mpl cytoplasmic domain are coupled to the JAK-STAT signal transduction pathway and Shc phosphorylation | Q34207417 | ||
| JAK2 and MPL protein levels determine TPO-induced megakaryocyte proliferation vs differentiation. | Q34293019 | ||
| Stat5 regulates cellular iron uptake of erythroid cells via IRP-2 and TfR-1. | Q34293299 | ||
| JAKs and STATs in immunity, immunodeficiency, and cancer | Q34321767 | ||
| Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F. | Q34375134 | ||
| Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling | Q34378552 | ||
| CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms. | Q34485103 | ||
| The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction | Q34527668 | ||
| mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms | Q34575726 | ||
| The JAK2 V617F somatic mutation, mortality and cancer risk in the general population | Q34612649 | ||
| The thrombopoietin receptor, MPL, is critical for development of a JAK2V617F-induced myeloproliferative neoplasm | Q34737531 | ||
| Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. | Q34752547 | ||
| STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: a critical role of STAT3 in innate immunity | Q34762373 | ||
| MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia | Q34770384 | ||
| Distinct effects of concomitant Jak2V617F expression and Tet2 loss in mice promote disease progression in myeloproliferative neoplasms | Q34876785 | ||
| The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms | Q35132280 | ||
| JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response | Q35163764 | ||
| Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms | Q35407362 | ||
| ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation | Q35484880 | ||
| Molecular insights into regulation of JAK2 in myeloproliferative neoplasms | Q35661987 | ||
| Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model | Q35849674 | ||
| The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling | Q35857092 | ||
| Critical requirement for Stat5 in a mouse model of polycythemia vera | Q35885303 | ||
| Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice. | Q35885308 | ||
| Deletion of Stat3 enhances myeloid cell expansion and increases the severity of myeloproliferative neoplasms in Jak2V617F knock-in mice | Q36137458 | ||
| STAT1 promotes megakaryopoiesis downstream of GATA-1 in mice | Q36173581 | ||
| Effect of mutation order on myeloproliferative neoplasms | Q36320344 | ||
| Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin | Q36366315 | ||
| Lnk inhibits Tpo-mpl signaling and Tpo-mediated megakaryocytopoiesis | Q36402414 | ||
| Tryptophan at the transmembrane-cytosolic junction modulates thrombopoietin receptor dimerization and activation | Q36617037 | ||
| Hematopoietic-specific Stat5-null mice display microcytic hypochromic anemia associated with reduced transferrin receptor gene expression | Q36843802 | ||
| Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden | Q36868686 | ||
| An activating mutation in the CSF3R gene induces a hereditary chronic neutrophilia | Q37292779 | ||
| Inactivation of Stat5 in mouse mammary epithelium during pregnancy reveals distinct functions in cell proliferation, survival, and differentiation | Q37493064 | ||
| JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. | Q37623539 | ||
| New mutations and pathogenesis of myeloproliferative neoplasms. | Q37886439 | ||
| The JAK-STAT pathway at twenty | Q38004201 | ||
| JAK2 the future: therapeutic strategies for JAK-dependent malignancies | Q38045061 | ||
| Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance | Q38081267 | ||
| Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms. | Q38167432 | ||
| An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms | Q38179853 | ||
| Therapy for myeloproliferative neoplasms: when, which agent, and how? | Q38282813 | ||
| Loss of TET2 has dual roles in murine myeloproliferative neoplasms: disease sustainer and disease accelerator | Q38303071 | ||
| Tuning cytokine receptor signaling by re-orienting dimer geometry with surrogate ligands | Q38625843 | ||
| Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy | Q38824881 | ||
| Orientation-specific signalling by thrombopoietin receptor dimers. | Q39592020 | ||
| Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group | Q39766394 | ||
| Characterization of murine JAK2V617F-positive myeloproliferative disease | Q40200859 | ||
| Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia. | Q40215071 | ||
| Critical role of Jak2 in the maintenance and function of adult hematopoietic stem cells. | Q40900721 | ||
| Common germline variation at the TERT locus contributes to familial clustering of myeloproliferative neoplasms | Q42033175 | ||
| Aberrant cytokine production by nonmalignant cells in the pathogenesis of myeloproliferative tumors and response to JAK inhibitor therapies | Q42239094 | ||
| Selective deletion of Jak2 in adult mouse hematopoietic cells leads to lethal anemia and thrombocytopenia. | Q42385056 | ||
| LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations | Q42931701 | ||
| Nanomolar-Potency Small Molecule Inhibitor of STAT5 Protein | Q43009401 | ||
| Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. | Q43031345 | ||
| Erythropoietin induces the tyrosine phosphorylation, nuclear translocation, and DNA binding of STAT1 and STAT5 in erythroid cells | Q70825978 | ||
| Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders | Q82828367 | ||
| p53 lesions in leukemic transformation | Q83352019 | ||
| JAK inhibitor in CALR-mutant myelofibrosis | Q87472426 | ||
| JAK inhibitor in CALR-mutant myelofibrosis | Q87472427 | ||
| Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis | Q24316448 | ||
| Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2 | Q24568313 | ||
| JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis | Q24609999 | ||
| Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality | Q24685515 | ||
| Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F | Q27670859 | ||
| Modulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode Dependent | Q27681086 | ||
| Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition | Q27683852 | ||
| A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms | Q27851467 | ||
| Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML | Q27852275 | ||
| Fetal anemia and apoptosis of red cell progenitors in Stat5a-/-5b-/- mice: a direct role for Stat5 in Bcl-X(L) induction | Q28140805 | ||
| A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera | Q28241887 | ||
| Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways | Q28306960 | ||
| TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis | Q28507642 | ||
| Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation | Q28508217 | ||
| Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses | Q28592023 | ||
| Activation of transcription by IFN-gamma: tyrosine phosphorylation of a 91-kD DNA binding protein | Q28646262 | ||
| Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis | Q29614337 | ||
| Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease | Q29615967 | ||
| A gain-of-function mutation of JAK2 in myeloproliferative disorders | Q29618851 | ||
| Mutation in TET2 in myeloid cancers | Q29619292 | ||
| CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons | Q29998841 | ||
| Molecular basis for pseudokinase-dependent autoinhibition of JAK2 tyrosine kinase | Q30658298 | ||
| JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. | Q33371084 | ||
| JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms | Q33383709 | ||
| JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis | Q33399977 | ||
| A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis | Q33399980 | ||
| Thrombocytopenia in c-mpl-deficient mice | Q33491977 | ||
| JAK2 V617F constitutive activation requires JH2 residue F595: a pseudokinase domain target for specific inhibitors | Q33618917 | ||
| AKT is a therapeutic target in myeloproliferative neoplasms | Q33623277 | ||
| Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis | Q33697252 | ||
| CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia. | Q33909621 | ||
| The molecular regulation of Janus kinase (JAK) activation | Q33956113 | ||
| Essential role of STAT3 in the control of the acute-phase response as revealed by inducible gene inactivation [correction of activation] in the liver | Q33967216 | ||
| Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms | Q33982315 | ||
| Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors | Q33982322 | ||
| Somatic mutations of calreticulin in myeloproliferative neoplasms | Q34039270 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pathogenesis | Q372016 |
| P304 | page(s) | 599-608 | |
| P577 | publication date | 2015-08-01 | |
| P1433 | published in | Experimental Hematology | Q5421109 |
| P1476 | title | Pathogenesis of myeloproliferative neoplasms | |
| P478 | volume | 43 |
| Q38738768 | A link between the driver mutations and dysregulated apoptosis in BCR-ABL1 negative myeloproliferative neoplasms. |
| Q36625047 | A novel interaction between megakaryocytes and activated fibrocytes increases TGF-β bioavailability in the Gata1(low) mouse model of myelofibrosis |
| Q33732661 | A novel, somatic, transforming mutation in the extracellular domain of Epidermal Growth Factor Receptor identified in myeloproliferative neoplasm. |
| Q57075545 | Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy |
| Q33443580 | Anti-Platelet Factor 4/Heparin Antibody Formation Occurs Endogenously and at Unexpected High Frequency in Polycythemia Vera. |
| Q52948095 | Bone marrow microvessel density and plasma angiogenic factors in myeloproliferative neoplasms: clinicopathological and molecular correlations. |
| Q38378147 | CAL2 Immunohistochemical Staining Accurately Identifies CALR Mutations in Myeloproliferative Neoplasms |
| Q49332507 | Clonogenic versus morphogenic mutations in myeloid neoplasms: chronologic observations in a U2AF1, TET2, CSF3R and JAK2 'co-mutated' myeloproliferative neoplasm suggest a hierarchical order of mutations and potential predictive value for kinase inhi |
| Q64938451 | Curcumin induces apoptosis in JAK2-mutated cells by the inhibition of JAK2/STAT and mTORC1 pathways. |
| Q90749981 | Experimental Modeling of Myeloproliferative Neoplasms |
| Q54216481 | Genomic alterations of the JAK2 and PDL loci occur in a broad spectrum of lymphoid malignancies. |
| Q38672646 | High-throughput sequencing for noninvasive disease detection in hematologic malignancies. |
| Q93064525 | Identification of functionally primitive and immunophenotypically distinct subpopulations in secondary acute myeloid leukemia by mass cytometry |
| Q46276799 | JAK2(V617I) results in cytokine hypersensitivity without causing an overt myeloproliferative disorder in a mouse transduction-transplantation model |
| Q61775217 | Janus kinase 2 activation mechanisms revealed by analysis of suppressing mutations |
| Q58701086 | Megakaryocyte Contribution to Bone Marrow Fibrosis: many Arrows in the Quiver |
| Q28076096 | Monitoring Minimal Residual Disease in the Myeloproliferative Neoplasms: Current Applications and Emerging Approaches |
| Q38684403 | Obesity and related risk of myeloproliferative neoplasms among israeli adolescents |
| Q64008493 | Oncogenic activation of MPL/thrombopoietin receptor by 17 mutations at W515: implications for myeloproliferative neoplasms |
| Q92546445 | Oral idasanutlin in patients with polycythemia vera |
| Q33443246 | The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation |
| Q47581193 | The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium |
| Q26773192 | The Hematopoietic Niche in Myeloproliferative Neoplasms |
| Q37571181 | The Role of IL-33-Dependent Inflammation in the Tumor Microenvironment. |
| Q60044440 | The epidemiology and clinical characteristics of myeloproliferative neoplasms in Malaysia |
Search more.